Company Overview and News

 
Is Guggenheim Multi-Asset Income ETF (CVY) a Hot ETF Right Now?

2018-05-23 zacks
Launched on 09/21/2006, the Guggenheim Multi-Asset Income ETF (CVY - Free Report) is a smart beta exchange traded fund offering broad exposure to the Total Market (U.S.) ETFs category of the U.S. equity market.

 
FDIC-Insured Banks' Q1 Earnings Impressive, Revenues Up

2018-05-23 zacks
Federal Deposit Insurance Corporation (FDIC)-insured commercial banks and savings institutions reported first-quarter 2018 earnings of $56 billion, up 27.5% year over year. Notably, community banks, constituting 92% of all FDIC-insured institutions, reported net income of $6.1 billion, up 17.7% on a year-over-year basis. Banks’ earnings were driven by higher net operating revenues and a lower effective tax rate.

1
Will Banks Benefit From the Easing of Dodd-Frank Rules?

2018-05-23 zacks
The long-time demand of banks to scale back stringent regulations is finally a reality. The House passed a crucial bill easing some provisions of the 2010 Dodd-Frank Act that were put in place as safeguard against repeat of the 2008 financial crisis. The House passed the bill on Tuesday backed by majority voting of 258 to 159, promising it to be beneficial for small and mid-sized banks. It would now be presented to President Donald Trump for signing, with the Senate already having passed the legislation in March.

 
Stock Market News For May 21, 2018

2018-05-21 zacks
Markets closed lower on Friday as trade negotiations between the United States and China continued to weigh on investors’ sentiment. Also, bond yields reached their highest level since 2011 last week. Bank stocks in particular took a hit. The S&P 500 and Nasdaq closed in the red, while the Dow barely managed to end the day higher.

4
Tracking David Tepper's Appaloosa Management Portfolio - Q1 2018 Update

2018-05-21 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q4 2017.

 
Bank Stock Roundup: Investor Confidence Shaken, Wells Fargo & Citi in Focus

2018-05-18 zacks
Over the last five trading days, banking stocks put up a lackluster show. Though improving U.S. economic data and rising 10-year Treasury bond yields were positives, investors were a bit concerned on the time uncertainty related to the easing of banking regulations and soft loan growth. Nevertheless, strong economy and increasing commodity prices aided a rise in bond yields followed by mortgage rates.

 
U.S. Supreme Court Allows Sports Betting: Now What For Investors?

2018-05-18 seekingalpha
The landmark court decision unleashes what could be a $150 billion industry within the next five years.

 
Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
The largest three positions are Alliance Data Systems, Charles Schwab, and Alphabet, and they add up to ~42% of the portfolio.

 
NBY / NovaBay Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has 10 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,828,053 shares. Largest shareholders include Op Financial Ltd, Bank Of America Corp /de/, Vanguard Group Inc, BlackRock Inc., Nvwm, Llc, UBS Group AG, Morgan Stanley, Genovese Burford & Brothers Wealth & Retirement Plan Management, LLC, and Royal Bank Of Canada.

 
Successful Trade Negotiations With China Could Be Quite Rewarding

2018-05-17 seekingalpha
I cannot think of a more appropriate time than now to drill down into the cornerstone of the trade issues with China. We must have a clear understanding of the trade issues before deciding the merits of investing. The more macro issues, such as currency manipulation and dumping practices, are certainly major concerns and must be addressed in our trade negotiations.

 
The World’s 15 Largest Banks

2018-05-17 247wallst
Of the world’s 15 largest banks, the top four are based in China. These four giants topped the list in 2016 and in 2017, so it’s no surprise at all that there has been no change at the top.

 
Bank Of America: This 6.00% Preferred Stock Has Begun Trading On The NYSE

2018-05-17 seekingalpha
In this article, we want to shed light on a new Preferred Stock issued by Bank Of America Corporation (BAC).

8
Tracking George Soros' Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.

 
Why is BofA (BAC) Up 4% Since Last Earnings Report?

2018-05-16 zacks
It has been about a month since the last earnings report for Bank of America Corporation (BAC - Free Report) . Shares have added about 4% in that time frame.

6
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...